lenvatinib, cisplatin

2 trials

Sponsors

Yamashita Taro

Conditions

Hepatocellular carcinoma Hepatocellular carcinoma

Phase 2

Lenvatinib plus Cisplatin refractory or unsuitable for ICI

Active, not recruitingJPRN-jRCT1041210163

Yamashita TaroHepatocellular carcinoma Hepatocellular carcinoma

Start: 2022-03-24Target: 60Updated: 2026-06-29

NAC Lenvatinib plus Cisplatin

RecruitingJPRN-jRCT1041220110

Yamashita TaroHepatocellular carcinoma Hepatocellular carcinoma

Start: 2023-01-12Target: 30Updated: 2026-06-29